髄膜炎とは、脳や脊髄を覆っている保護膜にウイルスや細菌が感染して起こる炎症のことです。炎症の原因は、ウイルスや細菌などの微生物による感染と、あまり一般的ではありませんが、特定の薬物による感染があります。炎症が脳や脊髄に近接するため、髄膜炎は生命を脅かす可能性があります。ウイルス性髄膜炎は命に別状はなく、かかった人もすぐに治って回復しますが、細菌性髄膜炎は重症で命に別状があります。細菌性髄膜炎を引き起こす細菌は、大きく分けて3つあります。髄膜炎菌はそのうちの一つで、髄膜炎菌性髄膜炎を引き起こします。研究者は髄膜炎菌の 13 の主要な血清群を特定しており、そのうち大部分の症例は、A、B、C、Y、および W-135 の 5 つの血清群のいずれかに属しています。血清群AC、C、ACWY、およびAを治療するための薬とワクチンが利用できます。また、血清群A、C、Y、W-135によって引き起こされる髄膜炎を予防するためのワクチンも利用できます。血清群Bによる髄膜炎菌性髄膜炎の予防と治療には、ワクチンや薬がないため、市場における大きなアンメットニーズとなっています。肺炎球菌による髄膜炎はもう一つの主要な細菌性髄膜炎で、肺炎球菌という細菌によって引き起こされ、ヘモフィルス・インフルエンザは第3の髄膜炎で、乳児に髄膜炎を引き起こします。細菌性髄膜炎の約44〜46％の症例では、激しい頭痛、項部硬直（首の筋肉の緊張が高まり、受動的に首を前に曲げることができない）、精神状態の変化という3つの症状をすべて併せ持ちます。この3つの症状のうち、激しい頭痛が最も多く、90％の症例に認められます。上記のような症状がない場合は、細菌性髄膜炎の可能性は低いと考えられます。その他の臨床的特徴としては、羞明（明るい光に対する恐怖）、羞音（大きな音に対する恐怖）などがあります。小さな子どもでは、上記のような症状を見つけることは困難です。過敏症や体調不良といった漠然とした症状が多くみられます。生後 6 か月までの乳児では、泉門 (赤ちゃんの頭の柔らかい部分) の膨らみが見られることがあります。極端な寒さ、皮膚の色の異常、足の痛みなど、それほどひどくない他の病気も、髄膜炎の特徴になることがあります。
目次
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meningitis - Overview
Meningitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningitis - Companies Involved in Therapeutics Development
CanSino Biologics Inc
Chengdu Olymvax Biopharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Jiangsu Kunli Biopharmaceutical Co Ltd
LG Chem Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Linnaeus Bioscience Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Pfizer Inc
Serum Institute of India Pvt Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Meningitis - Drug Profiles
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
APX-2039 - Drug Profile
Product Description
Mechanism Of Action
CSB-015 - Drug Profile
Product Description
Mechanism Of Action
flucytosine - Drug Profile
Product Description
Mechanism Of Action
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
LBVD - Drug Profile
Product Description
Mechanism Of Action
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A and C] vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A] vaccine - Drug Profile
Product Description
Mechanism Of Action
MYC-053 - Drug Profile
Product Description
Mechanism Of Action
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases
Oct 23, 2022: Matinas BioPharma to present new MAT2203 (oral amphotericin B) data during IDWeek 2022
Oct 21, 2022: Matinas BioPharma announces positive interim data from the phase 2 EnACT trial of MAT2203 for the treatment of cryptococcal meningitis, exceeding primary endpoint threshold; patient survival in all-oral cohort 4 regimen currently 90%
Oct 19, 2022: Matinas BioPharma announces Infectious Diseases Society of America (IDSA) has selected the EnACT phase 2 trial abstract of MAT2203 as its outstanding abstract and IDSA awardee for IDWeek 2022
Dec 16, 2021: Matinas BioPharma announces unanimous DSMB approval to progress into fourth and final cohort of patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Sep 13, 2021: Matinas BioPharma announces positive data in the ongoing EnACT trial of MAT2203 (Oral Amphotericin B) for the treatment of cryptococcal meningitis, exceeding the prespecified primary endpoint threshold
Aug 16, 2021: Matinas BioPharma announces issuance of U.S. patent protecting MAT2203 to treat or prevent cryptococcus infections
Oct 19, 2020: Matinas BioPharma announces unanimous DSMB approval to progress into second cohort of patients in the EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Aug 20, 2020: Matinas BioPharma announces publication of results from phase 1 portion of the EnACT study investigating safety and tolerability of MAT2203
Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis
Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis
Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational
May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio
May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Meningitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Meningitis - Pipeline by CanSino Biologics Inc, 2022
Meningitis - Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Meningitis - Pipeline by Jiangsu Kunli Biopharmaceutical Co Ltd, 2022
Meningitis - Pipeline by LG Chem Ltd, 2022
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022
Meningitis - Pipeline by Linnaeus Bioscience Inc, 2022
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, 2022
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, 2022
Meningitis - Pipeline by Pfizer Inc, 2022
Meningitis - Pipeline by Serum Institute of India Pvt Ltd, 2022
Meningitis - Pipeline by TGV Therapeutics, 2022
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, 2022
Meningitis - Dormant Projects, 2022
Meningitis - Dormant Projects, 2022 (Contd..1)
Meningitis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Meningitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
